Updated 5:04 p.m.
King & Spalding has added a partner to its Food and Drug Administration and life sciences practice, the firm announced Wednesday.
Michael Petty, the former vice president of development and regulatory law at biotechnology company Amgen Inc., joins King & Spalding in its Washington office. Petty, who spent six years with Amgen, offered legal support on corporate regulatory affairs, global health economics, pharmaceutical biotechnology, medical devices, and compliance. He also offers legal advice on the development operations for pharmaceuticals, biotechnology products and medical devices.
Before joining Amgen, Petty was a partner at Ropes & Gay and also served as associate chief counsel for enforcement at the FDA. At the FDA, Petty handled civil, criminal and enforcement matters.
"With a strong skill set, extensive experience and deep technical expertise in pharmaceutical and biotechnology regulatory matters, Michael brings additional strength to our team," Edward Basile, chair of King & Spalding’s FDA and life sciences practice, said in a written statement.
In an interview, Petty said that working in the private sector gives attorneys a better understanding of the needs of clients. He said he had worked closely with several King & Spalding attorneys when he used them as outside counsel while at Amgen.
"Not only do I know the vast majority of the FDA practice group, but I know their work," Petty said.